Published • loading... • Updated
Cigna Drops Coverage of GLP-1 Obesity Drugs for Its Own Employees
Reuters reported the change as Cigna said it is ending coverage for GLP-1 weight-loss drugs in its employee health plan.
- Health insurer Cigna will stop covering GLP-1 weight loss drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, in its employee health plan effective July 1, according to documents viewed by the company.
- As new manufacturer options have emerged, Cigna stated it remains committed to supporting employees' health through a range of weight management programs and resources rather than covering the injectable medications.
- Documents circulated to staff suggest employees currently using the medications can continue access by paying with cash through manufacturer-sponsored programs and discount sites.
- New options include Novo Nordisk's Wegovy pill and Eli Lilly's oral Foundayo, which feature prices starting at $149 per month for the lowest doses available to consumers.
- The decision reflects broader industry cost pressures surrounding GLP-1 drugs, which promote weight loss by mimicking a hormone that keeps the stomach feeling full.
Insights by Ground AI
31 Articles
31 Articles
The Billings Gazette+3 Reposted by 3 other sources
Cigna drops employee coverage of GLP-1 drugs
NEW YORK — Health insurer Cigna will stop covering GLP-1 weightloss drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, in its employee health plan effective July 1, according to materials viewed
·Billings, United States
Read Full ArticleCoverage Details
Total News Sources31
Leaning Left2Leaning Right0Center29Last UpdatedBias Distribution94% Center
Bias Distribution
- 94% of the sources are Center
94% Center
C 94%
Factuality
To view factuality data please Upgrade to Premium
